Regeneron – Introduction
Regeneron is a leader in the discovery of antibody drugs. It has more than 12 antibody treatments in development, of which three are in Phase II or III. The company has one approved molecule for retinal disorders, Eylea, which competes in the US$7.5bn global VEGF Trap-Eye market.
Link to the biotechnology report